###begin article-title 0
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: A preliminary study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 746 754 <span type="species:ncbi:9606">patients</span>
Early relapse in colorectal cancer (CRC) patients is attributed mainly to the higher malignant entity (such as an unfavorable genotype, deeper tumor invasion, lymph node metastasis and advance cancer stage) and poor response to chemotherapy. Several investigations have demonstrated that genetic polymorphisms in drug-targeted genes, metabolizing enzymes, and DNA-repairing enzymes are all strongly correlated with inter-individual differences in the efficacy and toxicity of many treatment regimens. This preliminary study attempts to identify the correlation between genetic polymorphisms and clinicopathological features of CRC, and evaluates the relationship between genetic polymorphisms and chemotherapeutic susceptibility of Taiwanese CRC patients. To our knowledge, this study discusses, for the first time, early cancer relapse and its indication by multiple genes.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1 </italic>
###xml 90 96 90 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
###xml 178 184 178 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 198 205 198 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 A</italic>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">Patients</span>
###xml 623 630 <span type="species:ncbi:9606">patient</span>
Six gene polymorphisms functional in drug-metabolism - GSTP1 Ile105Val, ABCB1 Ile1145Ile, MTHFR Ala222Val, TYMS double (2R) or triple (3R) tandem repeat - and DNA-repair genes - ERCC2 Lys751Gln and XRCC1 Arg399Gln - were assessed in 201 CRC patients using a polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) technique and DNA sequencing. Patients were diagnosed as either high-risk stage II (T2 and 3 N0 M0) or III (any T N1 and 2 M0) and were administered adjuvant chemotherapy regimens that included 5-fluorouracil (5FU) and leucovorin (LV). The correlations between genetic polymorphisms and patient clinicopathological features and relapses were investigated.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 43 45 43 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1 </italic>
###xml 62 64 62 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
###xml 80 82 80 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 100 102 100 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 116 122 116 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 123 125 123 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 191 197 191 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 198 200 198 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 319 325 319 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 334 336 334 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 368 370 368 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 403 405 403 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 432 434 432 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 515 521 515 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 493 501 <span type="species:ncbi:9606">Patients</span>
In this study, the distributions of GSTP1 (P = 0.003), ABCB1 (P = 0.001), TYMS (P < 0.0001), ERCC2 (P < 0.0001) and XRCC1 (P = 0.006) genotypes in the Asian population, with the exception of MTHFR (P = 0.081), differed significantly from their distributions in a Caucasian population. However, the unfavorable genotype ERCC2 2251A>C (P = 0.006), tumor invasion depth (P = 0.025), lymph node metastasis (P = 0.011) and cancer stage (P = 0.008) were significantly correlated with early relapse. Patients carrying the ERCC2 2251AC or2251CC genotypes had a significantly increased risk of early relapse (OR = 3.294, 95% CI, 1.272-8.532).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
We suggest that ERCC2 2251A>C alleles may be genetic predictors of early CRC relapse.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 347 348 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 606 607 606 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 608 609 608 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
The primary treatment for colorectal cancer (CRC) is resection of the primary tumor. After surgery, patients are frequently administered adjuvant chemotherapy to eliminate cancer cells that may have metastasized [1]. Despite chemotherapy, CRC remains the third major cause of cancer-related death in Taiwan, accounting for >3,000 deaths per year [2]. The overall five-year survival is 50-60% in European countries [3], a result similar to that in Taiwan [4]. The primary cause of death is distant and loco-regional relapses. Notably, CRC relapse is strongly correlated with chemotherapeutic drug response [1,5,6].
###end p 11
###begin p 12
###xml 46 47 46 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 48 49 48 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 74 75 74 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 576 582 576 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 775 781 775 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC1 </italic>
###xml 790 796 790 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 834 840 834 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 851 857 851 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 963 965 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 966 968 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1142 1143 1142 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 688 696 <span type="species:ncbi:9606">patients</span>
Genetic polymorphisms in drug-targeted genes [7,8], metabolizing enzymes [9], and DNA-repairing enzymes [10] have been linked to inter-individual differences in the efficacy and toxicity of numerous drugs. Several studies have investigated various gene expressions and chemotherapeutic drug responses of cancers. For instance, a polymorphic 28-bp tandem double repeat polymorphism in the regulatory region of the TYMS gene is correlated with a better response to 5-fluorouracil (5 FU) chemotherapy than the triple repeat in the polymorphism [11]. A common polymorphism in the MTHFR gene (677C>T; Ala222Val) increases the efficacy of fluoropyrimidine-based chemotherapy [12]. In Caucasian patients with advanced CRC who are treated with oxaliplatin, 5 FU and leucovorin (LV), ERCC1 118 T/T, XRCC1 (Arg - >Gln substitution in exon 10), ERCC2 751AC, and ERCC2 751CC genotypes are independently associated with poor progression-free survival and short-term survival [13,14]. Glutathione S-transferases (GSTs) participate in the detoxification of platinum compounds and are important mediators of intrinsic and acquired resistance to oxaliplatin [8].
###end p 12
###begin p 13
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
Advanced CRC is one of the most chemotherapy-resistant human malignancies. The cytotoxic agent with the most consistent antitumor activity is 5 FU. However, significant variability in drug response can occur among cancer patients treated with the same medications [15]. Elevated levels of thymidylate synthase (TS) are correlated with resistance to 5 FU and a poor clinical outcome [16-19].
###end p 13
###begin p 14
###xml 360 365 360 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 397 402 397 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1</italic>
###xml 428 433 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 472 476 472 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS</italic>
###xml 500 505 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2</italic>
###xml 594 599 594 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1</italic>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 842 850 <span type="species:ncbi:9606">patients</span>
###xml 1048 1056 <span type="species:ncbi:9606">patients</span>
###xml 1224 1232 <span type="species:ncbi:9606">patients</span>
###xml 1308 1316 <span type="species:ncbi:9606">patients</span>
Conventional regimens for treating cancer patients with chemotherapy do not account for interpatient variability in the expression of particular target genes. Such variability results in unpredictable tumor responses and host toxicity. This hospital-based study investigates the role of multiple genetic polymorphisms of six metabolizing and DNA-repair genes (GSTP1, Glutathione S-transferase P1; ABCB1, multidrug resistance 1; MTHFR, methylenetetrahydrofolate reductase; TYMS, thymidylate synthase; ERCC2, excision repair cross-complementing rodent repair deficiency, complementation group 2; XRCC1, X-ray cross-complementing 1) in literature, genomic databases, and the Medline database [10-12,20-23]. The correlations between single nucleotide polymorphisms of the six candidate genes and clinicopathological features of 201 Taiwanese CRC patients, in addition to the relationship between genetic variants and post-therapy early relapse, were also analyzed to elucidate the roles of genotypes of these six genes as predictors of response of CRC patients following 5 FU/LV chemotherapy. Furthermore, this study reviewed current literature regarding the distribution of these six candidate genes and their genotypes in CRC patients of different ethnic groups, and compared differences between Taiwanese CRC patients and those of other races.
###end p 14
###begin p 15
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
This is the first investigation of clinical outcome using multiple chemotherapeutic drug-related genetic polymorphisms for Taiwanese patients with advanced CRC. The ability to predict with a high degree of accuracy which patients are likely to respond to treatment and those who are unlikely to respond will significantly influence the design of new treatment regimens.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and specimens
###end title 17
###begin p 18
###xml 1302 1304 1300 1302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1384 1386 1382 1384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 2264 2266 2262 2264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 288 296 <span type="species:ncbi:9606">Patients</span>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
###xml 716 724 <span type="species:ncbi:9606">Patients</span>
###xml 1188 1196 <span type="species:ncbi:9606">Patients</span>
###xml 1922 1930 <span type="species:ncbi:9606">Patients</span>
Enrolled in this prospective study were 201 Taiwanese high-risk International Union Against Cancer (UICC) stage II and stage III CRC patients (median age, 62.09 +/- 12.67 years) who were admitted to the Department of Surgery at Kaohsiung Medical University Hospital for elective surgery. Patients with other malignant diseases in their medical history were excluded. All 201 patients underwent radical resection for a primary lesion. Radical resection was defined as any gross residual tumor that did not remain in the surgical bed, and the surgical resection margin is pathologically negative for tumor invasion. All patients were diagnosed as either high-risk stage II (T2 and 3 N0 M0) or III (any T N1 and 2 M0). Patients with risk factors for relapse (tumor poorly differentiated, tumor perforation, number of lymph nodes examined <12 or lymphatic/vascular invasion) were considered high-risk stage II cases. Written informed consent was obtained from all subjects and/or guardians for use of their blood samples. The follow-up endpoint was June 2007. Sample acquisition and subsequent use were approved by the institutional review board at the Kaohsiung Medical University Hospital. Patients were administered six 8-week cycles of adjuvant chemotherapy. Each cycle consisted of leucovorin 500 mg/m2 administered as a 2-h infusion and given weekly for six doses, and 5 FU 500 mg/m2 administered as an intravenous bolus 1 h after the start of leucovorin infusion and repeated weekly for 6 doses. This cycle was then repeated after a 2-week rest period. Postoperative surveillance consisted of comprised medical history, physical examination, and laboratory studies, including assessing serum carcinoembryonic antigen (CEA) levels at 3-month intervals. Abdominal ultrasonography or computed tomography was performed at 6-month intervals, and chest radiography, bone scans, and total colonoscopy were performed annually. Patients were followed up at 3-month intervals for 2 years and at 6-month intervals thereafter. Median follow-up time was 34.2 months (range, 24-40 months). Clinical stage and pathological features of primary tumors were defined according to criteria of the American Joint Commission on Cancer/International Union Against Cancer (AJCC/UICC) [24].
###end p 18
###begin p 19
Development of new post-operative recurrent or metastatic lesions was defined as postoperative relapse. Early relapse was defined as local recurrence (tumor growth restricted to the anastomosis or the region of the primary operation) or distant metastasis (distant metastasis or diffuse peritoneal seeding) within 1 year following radical resection.
###end p 19
###begin title 20
DNA extraction
###end title 20
###begin p 21
###xml 110 114 110 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Constitutional gene polymorphisms were analyzed via DNA extraction from 4 ml peripheral blood using a PUREGENE(R) DNA Isolation Kit (Gentra Systems, Inc., Minneapolis, MN, USA).
###end p 21
###begin title 22
PCR-RFLP
###end title 22
###begin p 23
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1</italic>
###xml 185 190 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS</italic>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2</italic>
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1</italic>
###xml 468 469 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 689 695 688 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 896 901 871 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BsmAI</italic>
###xml 1051 1057 1026 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1 </italic>
###xml 1258 1261 1209 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dpn</italic>
###xml 1397 1403 1348 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 1604 1608 1531 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hinf</italic>
###xml 1739 1744 1666 1671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
###xml 1969 1975 1878 1884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 2176 2179 2061 2064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pst</italic>
###xml 2323 2329 2208 2214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 2530 2533 2391 2394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
All genomic DNA from patients were examined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach to determine the genotypes of GSTP1, ABCB1, MTHFR, TYMS, ERCC2, and XRCC1. Following digestion with suitable restriction enzymes, PCR fragments were separated on a 2.5-3.0% agarose gel and visualized after ethidium bromide staining. This study also utilized the automated sequencing approach to confirm PCR-RFLP results (Figs. 1, 2, 3, 4). All primers utilized in this study were designed by using Primer3 freeware [25]. Table 1 presents the primer sequences and restriction enzymes. The PCR reaction volume was 40 muL. The PCR conditions, for the GSTP1 polymorphism were as follows: 95degreesC for 5 min, 35 cycles at 95degreesC for 30 s, annealing at 65degreesC for 10 s, and 72degreesC for 25 s. A 433-bp product was amplified following digestion with BsmAI. Digestion generated fragments of 329 and 104 bp for the A allele, and fragments of 222, 107, and 104 bp for the Gallele. The PCR conditions for the ABCB1 polymorphism were as follows: 95degreesC for 5 min, 35 cycles at 95degreesC for 30 s, annealing at 58degreesC for 15 s, and 72degreesC for 20 s. A 244-bp product was amplified following digestion with DpnII. Digestion generated fragments of 172 and 72 bp for the C allele, and a 244-bp fragment for the T allele. The PCR conditions for the MTHFR polymorphism were as follows: 95degreesC for 5 min, 35 cycles at 95degreesC for 30 s, annealing at 70degreesC for 20 s, and 72degreesC for 25 s. A 400-bp product was amplified following digestion with HinfI. Digestion produced a 400-bp fragment for the C allele, and 318 and 82 bp fragments for the T allele. The PCR conditions for the TYMS polymorphism were as follows: 95degreesC for 5 min, 35 cycles at 95degreesC for 30 s, and 72degreesC for 35 s. A 240- and 212-bp product was amplified for the 3R allele and 2R allele, respectively. The PCR conditions for the ERCC2 polymorphism were as follows: 95degreesC for 5 min, 35 cycles at 95degreesC for 30 s, annealing at 64degreesC for 10 s, and 72degreesC for 20 s. A 149-bp product was amplified following digestion with PstI. Digestion generated 143- and 6-bp fragments for the A allele, and fragments of 80, 63, and 6 bp for the C allele. The PCR conditions for the XRCC1 polymorphism were as follows: 95degreesC for 5 min, 35 cycles at 95degreesC for 30 s, annealing at 62degreesC for 20 s, and 72degreesC for 20 s. A 208-bp product was amplified following digestion with MspI. Digestion produced 156- and 52-bp fragments for the G allele, and a 208-bp fragment for the A allele.
###end p 23
###begin p 24
Characteristics of the studied polymorphisms with primer sequences and restriction enzymes
###end p 24
###begin p 25
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">PCR-RFLP analysis and automated sequencing of <italic>GSTP1 </italic>A313G</bold>
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 153 171 153 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 exon5 A313G </italic>
###xml 335 341 335 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 370 376 370 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 413 419 413 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
PCR-RFLP analysis and automated sequencing of GSTP1 A313G. Figures 1A-C present PCR-RFLP analysis results for GSTP1 single nucleotide polymorphisms. The GSTP1 exon5 A313G was restricted by BsmAI. Digestion resulted in 329 and 104 bp fragments for the A allele, and 222, 107, and 104 bp fragments for the G allele (Fig. 1A: The RFLP of GSTP1 results. Fig. 1B: Picture of GSTP1 313AA sequences. Fig. 1C: Picture of GSTP1 313GG sequences)
###end p 25
###begin p 26
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">PCR-RFLP analysis and automated sequencing of <italic>MTHFR </italic>C667T</bold>
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 158 164 158 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 182 186 182 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hinf</italic>
###xml 323 328 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 350 356 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 393 399 393 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
PCR-RFLP analysis and automated sequencing of MTHFR C667T. Figures 2A-C present PCR-RFLP analysis results for MTHFR single nucleotide polymorphisms. Notably, MTHFR was restricted by HinfI. Digestion resulted in a 400-bp fragment for the C allele, and 318 and 82 bp fragments for the T allele. (Fig. 2A: Results for RFLP of MTHFR. Fig. 2B: Picture of MTHFR 677CC sequences. Fig. 2C: Picture of MTHFR 677TT sequences)
###end p 26
###begin p 27
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">PCR-RFLP analysis and automated sequencing of <italic>ERCC2 </italic>A2251C</bold>
###xml 111 117 111 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 159 165 159 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 183 186 183 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 330 335 330 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2</italic>
###xml 357 363 357 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
PCR-RFLP analysis and automated sequencing of ERCC2 A2251C. Figures 3A-C present PCR-RFLP analysis results for ERCC2 single nucleotide polymorphisms. Notably, ERCC2 was restricted by MspI. Digestion resulted in 143 and 6 bp fragments for the A allele, and 80, 63, and 6 bp fragments for the C allele. (Fig. 3A: Result for RFLP of ERCC2. Fig. 3B: Picture of ERCC2 2251AA sequences. Fig. 3C: Picture of ERCC2 2251CC sequences)
###end p 27
###begin p 28
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
###xml 0 46 0 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink">PCR-RFLP analysis of <italic>TYMS </italic>repeat polymorphisms</bold>
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
PCR-RFLP analysis of TYMS repeat polymorphisms. Figure 4 presents PCR-RFLP analysis results for TYMS repeat polymorphisms. A 240-bp product was amplified for the 3R allele and a 212-bp product was amplified for the 2R allele.
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 518 520 516 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 629 631 627 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
All data were analyzed using the Statistical Package for the Social Sciences Version 12.0 (SPSS, Inc., Chicago, IL, USA). The correlation between a polymorphism and relapse status was assessed using the relative risk ratio and a 95% confidence interval (CI). This is an exploratory and hypothesis-generating study. To clarify the clinical significance of these combined genotypes as predictors of postoperative relapse, a multivariate adjustment was performed by logistic regression analysis. The two-sided Pearson chi2 test was applied to assess the differences in distributions of genotypes between different races. A value of P < 0.05 was considered statistically significant.
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics
###end title 32
###begin p 33
###xml 502 503 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
###xml 559 567 <span type="species:ncbi:9606">patients</span>
In total, 201 patients were enrolled. Of these, 118 were male (58.7%) and 83 were female (41.3%). Thirty-three patients (16.4%) were aged : <==50 years and 120 (59.7%) were >60 years (range, 33-75 years). Thirty cases (14.9%) developed early relapse, either local recurrence or distant metastasis, during follow-up. Primary tumor location for 146 cases (72.6%) was the colon and 55 (27.4%) was the rectum. In total, 105 cases (52.2%) were UICC stage II, and 96 cases (47.8%) were UICC stage III. Table 2 lists the other clinicopathological characteristics of patients and tumors.
###end p 33
###begin p 34
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Correlations between clinicopathological features and recurrence status for 201 postoperative colorectal cancer patients
###end p 34
###begin p 35
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aInternational Union Against Cancer
###end p 35
###begin title 36
Correlation between early relapse and clinicopathological data
###end title 36
###begin p 37
###xml 121 123 121 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 259 261 259 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 384 386 384 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 503 505 503 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 654 656 654 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
###xml 461 469 <span type="species:ncbi:9606">patients</span>
No statistical correlations existed between early relapse status and sex, age, tumor size, tumor location and histology (P > 0.05; Table 2). However, depth of tumor invasion, lymph node metastasis and cancer stage were significantly related to early relapse (P < 0.05). Risk of early relapse was higher in T3+T4 that had a deeper invasion than did T2 (OR, 1.205; 95% CI, 1.127-1.289; P = 0.025). Stage III patients had a higher early relapse rate than stage II patients (OR, 2.897; 95% CI, 1.243-6.381; P = 0.011), and early relapse was higher in cases with lymph node metastasis than those with no lymph node metastasis (OR, 2.987; 95% CI, 1.293-6.899; P = 0.008).
###end p 37
###begin title 38
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Comparison of genotype distributions between Taiwanese CRC patients and those of other races
###end title 38
###begin p 39
###xml 84 85 84 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 156 162 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1 </italic>
###xml 211 217 211 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
###xml 277 283 277 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
To compare the genotypes of Taiwanese CRC patients with those of other races (Table 3), this study compared the distribution of gene polymorphisms, such as GSTP1 313A>G (AA, AG, GG), ABCB1 3435C>T (CC, CT, TT), MTHFR 677C>T (CC, CT, TT), TYMS tandem repeat (3R3R, 2R3R, 2R2R), ERCC2 2251A>C (AA, AC, CC) and XRCC1 1196G>A (GG, GA, AA), in various races, races - Caucasian, Japanese, Korean, Chinese, and Taiwanese. This study also included our findings from a literature review.
###end p 39
###begin p 40
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Comparison of genotype and allele frequencies (%) between Taiwanese colorectal cancer patients and those of other ethnic groups
###end p 40
###begin p 41
###xml 6 12 6 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">author</italic>
###xml 12 14 12 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 12 14 12 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n </italic></sup>
###xml 65 66 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic></sup>
NOTE: authorn in this table is designated by a reference number (n) and the abbreviated name of the first author in the previously paper.
###end p 41
###begin p 42
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 229 235 229 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 320 322 320 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 423 425 423 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
For GSTP1, 129 (64.2%) were AA, 66 (32.8%) were AG and 6 (3.0%) were GG genotype carriers, as compared with Caucasians [26] (AA, 42%; AG, 47.4%; GG, 10.6%) and Taiwanese [27] (AA, 67.9%; AG, 28.7%; GG, 3.4%). The distribution of GSTP1 313A>G genotypes in our data differed significantly from that of Caucasian patients (P = 0.003); however, no significant differences existed when compared with previous Taiwanese studies (P = 0.827).
###end p 42
###begin p 43
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1</italic>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 278 284 278 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1 </italic>
###xml 355 357 355 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 421 423 421 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 457 459 457 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
For ABCB1, 70 (34.8%) were CC, 104 (51.8%) were CT and 27 (13.4%) were TT genotype carriers, as compared with Caucasians [28] (CC, 22.3%; CT, 44%; TT, 33.7%), Japanese [29] (CC, 29.2%; CT, 58.3%; TT, 12.5%) and Korean [30] (CC, 28.8%; CT, 56.8%; TT, 14.4%). The distribution of ABCB1 3435C>T genotypes was significantly different from that in Caucasians (P = 0.001) and not significantly different from that in Japanese (P = 0.641), and Korean populations (P = 0.661).
###end p 43
###begin p 44
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 305 318 305 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR 677C&gt;T </italic>
###xml 319 329 319 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC, CT, TT</italic>
###xml 391 393 391 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 418 420 418 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 491 493 491 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
For MTHFR, 122 (60.7%) were CC, 72 (35.8%) were CT and 7 (3.5%) were TT genotype carriers, as compared with Caucasians [31] (CC, 46%; CT, 45%; TT, 9%), Japanese [32] (CC, 39.4%; CT, 48.2%; TT, 12.4%), and Korean [33] (CC, 35.4%; CT, 50.2%; TT, 14.4%) populations. Significantly different distributions of MTHFR 677C>T (CC, CT, TT) genotypes existed when our data was compared with Japanese (P = 0.005) or Korean data (P = 0.001), and it does not significantly different from Caucasian data (P = 0.081).
###end p 44
###begin p 45
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS</italic>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
###xml 389 391 389 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 425 427 425 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 495 497 495 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
For TYMS, 135 (67.2%) were 3R/3R, 59 (29.3%) were 2R/3R, and 7 (3.5%) were 2R/2R genotype carriers, as compared with Caucasians (3R/3R, 32%; 3R/2R, 50%; 2R/2R, 18%), Japanese [34] (3R/3R, 69%; 3R/2R, 27%; 2R/2R, 4%), and Chinese [35] (3R/3R, 67%; 3R/2R, 31%; 2R/2R, 2%) populations. The highest expression of TYMS 3R/3R in this study of Taiwanese patients was similar to that of Japanese (P = 0.951) and Chinese populations (P = 0.693), but different from that of the Caucasian population [36] (P < 0.0001).
###end p 45
###begin p 46
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2</italic>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 241 247 241 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 310 312 310 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 372 374 372 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 430 436 430 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 535 541 535 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 619 625 619 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
For ERCC2, 176 (87.6%) were AA, 24 (11.9%) were AC, and 1(0.5%) were CC genotype carriers, as compared with Caucasians [37] (AA, 25%; AC, 61%; CC, 14%) and Taiwanese [38] (AA, 84%; AC, 15.6%; CC, 0.4%) populations. The highest expression of ERCC2 AA in this study was similar to that in a previous study [38] (P = 0.436) and different from that of a Caucasian population (P < 0.0001). Caucasian CRC cancer patients presented with ERCC2 AC as the most common polymorphism genotype. In this study and another previous Taiwanese studies, ERCC2 2251A>C AA was more common than AC and CC, while another study indicated that ERCC2 2251A>C AC was the most frequent genotype.
###end p 46
###begin p 47
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1</italic>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 289 295 289 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 345 347 345 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 385 387 385 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 450 452 450 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
For XRCC1, 124 (61.7%) were GG, 64 (31.8%) were GA and 13 (6.5%) were AA genotype carriers, as compared with Caucasian [37] (GG, 39%; GA, 52%; AA, 9%), Korean [39] (GG, 53.6%; GA, 42.1%; AA, 4.3%), and Taiwanese [38] (GG, 56.7%; GA, 36.2%; AA, 7.1%) populations. The highest expression of XRCC1 GG in this study was similar to that for Koreans (P = 0.257) and other Taiwanese studies (P = 0.802), but different from that of the Caucasian population (P = 0.006).
###end p 47
###begin title 48
Correlation between genetic polymorphisms with clinicopathological data
###end title 48
###begin p 49
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 336 338 336 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
This study assessed correlations between genetic polymorphisms and clinicopathological features of 201 Taiwanese CRC patients (Table 4). No statistically significant correlations existed between genotype distributions and sex, age, tumor site or location, depth of tumor invasion, lymph node metastasis, cancer stage, or histology (all P > 0.05).
###end p 49
###begin p 50
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Correlation between gene polymorphism and clinicopathological properties of 201 postoperative colorectal cancer patients
###end p 50
###begin p 51
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aInternational Union Against Cancer
###end p 51
###begin title 52
Correlation between early relapse and genetic polymorphisms
###end title 52
###begin p 53
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1 </italic>
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
###xml 126 132 126 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 281 287 281 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 370 372 370 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 400 405 400 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 407 412 407 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1</italic>
###xml 414 419 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 421 425 421 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS</italic>
###xml 431 437 431 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 482 484 482 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 498 499 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 534 540 534 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 551 557 551 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 661 663 661 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 320 328 <span type="species:ncbi:9606">patients</span>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
The correlations between gene polymorphisms (GSTP1 313A>G, ABCB1 3435C>T, MTHFR 667C>T, TYMS double or triple tandem repeats, ERCC2 2251A>C and XRCC1 1196G>A) and patients with or without early recurrence were examined. Statistical analyses indicate that genotype polymorphisms of ERCC2 were strongly correlated between patients with recurrent and non-recurrent tumors (P = 0.006; Table 5); however, GSTP1, ABCB1, MTHFR, TYMS, and XRCC1 genotypes polymorphisms were not correlated (P > 0.05; Table 5). The Taiwanese CRC patients with ERCC2 2251AC and ERCC2 2251CC genotypes have a risk of recurrence 3.294 times greater than that of those with other genotypes (P = 0.01; 95% CI, 1.272-8.532).
###end p 53
###begin p 54
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Distribution of gene polymorphisms in 201 colorectal cancer patients and regarding the status of recurrence after surgery
###end p 54
###begin title 55
Discussion
###end title 55
###begin p 56
###xml 543 551 <span type="species:ncbi:9606">patients</span>
###xml 622 630 <span type="species:ncbi:9606">patients</span>
This is an exploratory and hypothesis-generating study. This study attempted to move beyond single genetic polymorphisms to a more comprehensive investigation that identifies genomic variants and patterns and performed early relapse analysis. This study investigated six functional genomic polymorphisms in genes, which have different enzyme functions, or expressions, and DNA repair by PCR-RFLP assay and cycling sequencing. This is the first comprehensive study to investigate genotype frequencies of six gene polymorphisms in Taiwanese CRC patients. Additionally, this study analyzed the genotypes of 201 Taiwanese CRC patients and demonstrated that genotype distributions have ethnic variations.
###end p 56
###begin p 57
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
###xml 261 266 261 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS </italic>
###xml 379 385 379 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR </italic>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 570 571 570 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 587 589 587 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 600 602 600 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
In 5FU-related genes, the incidence of the TYMS gene promoter 3R/3R genotype in the 201 cases in this study is similar to that in Japanese [34] and Chinese [35] populations, and higher than that in Caucasian populations [36]. Neither the TYMS 2R allele nor the TYMS 3R allele is predominant in Caucasians; however, the TYMS 3R allele is predominant in Asian populations. For the MTHFR C677T polymorphism, the incidence of the 677CC genotype in this Taiwanese CRC population was higher than that for Caucasians [31], and Japanese [32], and Korean [33] populations (Table 3). Notably, the C allele and T allele frequencies in Caucasian and Asian populations are similar.
###end p 57
###begin p 58
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1 </italic>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
This study assessed the ABCB1 3435C>T of 201 Taiwanese CRC patients. The frequency of the TT genotype in the 201 Taiwanese patients is similar to that in Japanese [29] and Korean [30] patients, but lower than that in Caucasian populations [28]. The allele frequency of C and T did not differ between Caucasians and Asians.
###end p 58
###begin p 59
###xml 69 75 69 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 403 411 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
The genotype data for cell detoxification-related gene polymorphism, GSTP1 313A>G, are similar to that for 408 Taiwanese CRC patients in a study by Yen et al. [27]. Caucasian populations have an equal incidence of AA homozygotes and AG heterozygotes [26]; however, the Taiwanese population has more AA homozygotes than AG heterozygotes. The allele frequency of Ile is also more predominant in Taiwanese patients than in Caucasian patients.
###end p 59
###begin p 60
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 588 594 588 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 598 603 598 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2</italic>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 798 804 798 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 835 837 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 933 939 933 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 996 998 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1147 1153 1147 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 1247 1249 1247 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1396 1397 1396 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 206 211 <span type="species:ncbi:9606">human</span>
###xml 672 680 <span type="species:ncbi:9606">patients</span>
###xml 879 887 <span type="species:ncbi:9606">patients</span>
###xml 973 981 <span type="species:ncbi:9606">patients</span>
Since the genetic polymorphisms of DNA-repair enzymes may influence DNA adduct levels [40-42], the particular degree of DNA repair capacity can be utilized to identify genetically high-risk individuals for human cancers [43]. Resistance to platinum agents has been attributed to increased tolerance to platinum DNA adducts, enhanced DNA repair, or decreased drug accumulation [44]. Proteins of the nucleotide excision repair (NER) pathway, in particular, are believed play a central role in repair of DNA damage caused by platinum compounds. The enzymes related to the DNA repair system, XRCC1 and ERCC2, were similar to those identified in other studies of Taiwanese CRC patients [38]. Although very few studies have investigated these two polymorphisms in Asian CRC populations, the incidence of XRCC1 G1196A in a Korean population [39] is similar to that in the 201 Taiwanese patients in this study. However, the frequency of the XRCC1 GG homozygous and GA heterozygous patients in Caucasian [37] and Asian populations differ significantly. Moreover, the frequency of the G allele and A alleles do not differ between Caucasians and Asians. For ERCC2 2251A>C, the genotype and allele frequencies are dissimilar between Taiwanese and Caucasians [37]. Neither the A allele nor C allele has been identified as predominant in Caucasians, whereas the A allele is predominant in the Taiwanese (Table 3).
###end p 60
###begin p 61
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
###xml 301 309 <span type="species:ncbi:9606">patients</span>
###xml 706 714 <span type="species:ncbi:9606">patients</span>
###xml 864 872 <span type="species:ncbi:9606">patients</span>
In 2004, Shirao et al. compared the efficacy, toxicities, and pharmacokinetics of an oral regimen consisting of uracil/tegafur (UFT) and LV between Japanese patients and Caucasian patients in the United States [45]. Although the response rate did not differ (36.4% for Japanese patients and 34.1% for patients in the United States), a difference existed in toxicity profile, specifically the incidence of diarrhea - 9% in the Japanese population and 22% in the Caucasian population in the United States. Since genotype frequencies were similar between Japanese and Taiwanese populations, we suggest that cancer chemotherapy efficacy, toxicities, and pharmacokinetics would be similar to those for Japanese patients. Consequently, we hypothesize that these polymorphisms screened have the ability to predict toxicity, clinical outcome and survival in Taiwanese CRC patients. This hypothesis and suggestion warrant further investigation.
###end p 61
###begin p 62
###xml 224 226 224 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 259 261 259 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 289 291 289 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 343 349 343 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
Studies focusing on acute relapse risk of CRC and these metabolizing and DNA-repair genes are limited and controversial. In addition to the statistically significant role of early relapse, including depth of tumor invasion (P = 0.025), lymph node metastasis (P = 0.011), and cancer stage (P = 0.008), analytical results in this study indicate ERCC2 2251A>C AC and CC gene polymorphismswere statistically significant in predicting early relapse.
###end p 62
###begin p 63
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 261 267 261 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 433 439 433 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 513 519 513 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 640 645 640 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2</italic>
###xml 859 865 859 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 1024 1026 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1027 1029 1027 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1070 1076 1070 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 1153 1155 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1304 1310 1304 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 1569 1571 1569 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 249 255 <span type="species:ncbi:9606">humans</span>
###xml 1282 1290 <span type="species:ncbi:9606">patients</span>
The DNA repair systems play an important role in maintaining genomic integrity and preventing carcinogenesis [46]. At least four pathways for DNA repair operate on specific DNA damage types [47]. Nucleotide excision repair is the primary pathway in humans. The ERCC2 gene plays a dominant role in nucleotide excision repair and basal transcription, both of which are crucial to the elimination of bulky DNA adducts. Furthermore, the ERCC2 protein is essential for nucleotide excision repair activity [48,49]. The ERCC2 gene consists of 23 exons at 19q13.3. Several single nucleotide polymorphisms have been identified in the coding part of ERCC2, of which Ile199Met (C/G), His201Tyr (C/T), Asp312Asn (G/A), and Lys751Gln (A/C) result in amino acid changes; however, codon Arg156Arg (C/A) and Asp711Asp (C/T) are silent polymorphisms. The functional effect of ERCC2 polymorphisms remains unclear. The polymorphisms at codon 312 and 751 have been analyzed extensively for their potential ability to increase lung cancer risk [49,50]. Although an earlier study showed that ERCC2 homozygous variant individuals were at increased risk of adenomatous polyps [51], associations between DNA repair gene polymorphisms and CRC have not been explored extensively. This study suggests that CRC patients who have the ERCC2 2251AC (751Lys/Gln) or 2251CC (751Glu/Gln) genotypes have a significantly increased early relapse risk (OR = 3.294; 95% CI, 1.272-8.532), and no statistically significant correlation exists between genotype distributions and clinicopathological features (all P > 0.05).
###end p 63
###begin p 64
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 463 469 463 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 1014 1016 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 1020 1022 1020 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 1553 1555 1553 1555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1598 1604 1598 1604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
###xml 1168 1176 <span type="species:ncbi:9606">patients</span>
###xml 1409 1417 <span type="species:ncbi:9606">Patients</span>
###xml 1741 1749 <span type="species:ncbi:9606">patients</span>
This study examined potential genetic predictors of CRC relapse. A recent study [52] determined that the C(Glu) allele of the ERCC2 Lys751Gln variant allele marginally increased lung cancer risk (OR = 3.61, P = 0.04) in a Chinese population, and another identified [53] increased risk for squamous cell carcinoma of the head and neck in patients with the Gln/Gln genotype when compared with the Lys/Lys group. Experimental results in this study indicate that the ERCC2 2251A>C AC and CC gene polymorphisms can predict early relapse; these experimental results are in agreement with the risk role of the C (Glu) allele of ERCC2 Lys751Gln in early relapse. Inherited single nucleotide polymorphisms of DNA repair genes may contribute to variations in DNA repair capacity and susceptibility to cancer. The molecular functional effect of ERCC2 polymorphisms remains unclear. Although some researchers have identified incomplete repair of DNA damage or of aromatic DNA adducts in the presence of ERCC2 variant alleles [42,54-58], we hypothesize that the malignant entity of the C (Glu) allele of ERCC2 Lys751Gln is responsible for poor prognosis of early relapse among CRC patients receiving similar chemotherapeutic regimens in this study. In 2001, Park reported the finding of a significant relationship between clinical response to chemotherapy (combined oxaliplatin and 5FU) and ERCC2 Lys751Gln polymorphisms. Patients with the Gln/Gln genotype had significantly shorter survival or increased relative risk of dying when compared with the Lys/Lys group [10]. These experimental results suggest that ERCC2 2251A>C may indeed be of functional importance in Taiwanese CRC. Aggressive chemotherapy or combined radiotherapy will be considered for patients with this poor prognostic genotype.
###end p 64
###begin title 65
Conclusion
###end title 65
###begin p 66
###xml 75 81 75 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2 </italic>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
In conclusion, analytical data in this study suggest that the polymorphism ERCC2 A2251C is associated with risk of CRC early relapse in a Taiwanese population. Additionally, this study analyzed six gene polymorphisms associated with the clinical outcome of Taiwanese CRC patients. These genotypic frequencies vary among ethnic groups. Studies with relatively larger sample sizes are needed to elucidate the effects of these polymorphisms on early relapse risk in this population. However, experimental results in this study serve as a basis for large-scale correlational studies on the relevance of these variants in predicting early relapse of CRC in a Taiwanese population.
###end p 66
###begin title 67
Abbreviations
###end title 67
###begin p 68
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABCB1</italic>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 136 140 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TYMS</italic>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2</italic>
###xml 258 263 258 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1</italic>
CRC, colorectal cancer; GSTP1, Glutathione S-transferase P1; ABCB1, multidrug resistance 1; MTHFR, methylenetetrahydrofolate reductase; TYMS, thymidylate synthase; ERCC2, excision repair cross-complementing rodent repair deficiency, complementation group 2; XRCC1, X-ray cross-complementing1; PCR-RFLP, polymerase chain reaction restriction fragment length polymorphism.
###end p 68
###begin title 69
Competing interests
###end title 69
###begin p 70
The author(s) declare that they have no competing interests.
###end p 70
###begin title 71
Authors' contributions
###end title 71
###begin p 72
MYH analyzed the data and wrote the manuscript. WYF, SCL and TLC made substantial contributions in data acquisition, molecular genetic analyses, statistical analyses and data interpretation, and helped in manuscript preparation. JYW and SRL participated in study design and coordination. All authors read and approved the final manuscript.
###end p 72
###begin title 73
Pre-publication history
###end title 73
###begin p 74
The pre-publication history for this paper can be accessed here:
###end p 74
###begin p 75

###end p 75
###begin title 76
Acknowledgements
###end title 76
###begin p 77
The authors would like to thank the National Science Council of the Republic of China, Taiwan, for financially supporting this research under Contract No. NSC 94-2745-B-037-008-URD. Ted Knoy is appreciated for his editorial assistance.
###end p 77
###begin article-title 78
Current status of clinical studies for colorectal cancer in Taiwan
###end article-title 78
###begin article-title 79
Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT-11) in advanced 5-FU-refractory colorectal cancer: MTD definition and efficacy evaluation. A phase I-II study
###end article-title 79
###begin article-title 80
EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century
###end article-title 80
###begin article-title 81
Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5,474 cases in 20 years
###end article-title 81
###begin article-title 82
Adjuvant therapy of stage II and III colon cancer
###end article-title 82
###begin article-title 83
###xml 104 112 <span type="species:ncbi:9606">patients</span>
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
###end article-title 83
###begin article-title 84
Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1
###end article-title 84
###begin article-title 85
###xml 110 115 <span type="species:ncbi:9606">human</span>
Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells
###end article-title 85
###begin article-title 86
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis
###end article-title 86
###begin article-title 87
###xml 110 118 <span type="species:ncbi:9606">patients</span>
A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer
###end article-title 87
###begin article-title 88
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
###end article-title 88
###begin article-title 89
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate
###end article-title 89
###begin article-title 90
Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
###end article-title 90
###begin article-title 91
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
###end article-title 91
###begin article-title 92
Chemotherapy of colorectal cancer
###end article-title 92
###begin article-title 93
###xml 113 118 <span type="species:ncbi:9606">human</span>
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
###end article-title 93
###begin article-title 94
Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial
###end article-title 94
###begin article-title 95
Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer
###end article-title 95
###begin article-title 96
Thymidylate synthase pharmacogenetics in colorectal cancer
###end article-title 96
###begin article-title 97
###xml 111 117 <span type="species:ncbi:9606">humans</span>
Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans
###end article-title 97
###begin article-title 98
###xml 32 37 <span type="species:ncbi:9606">human</span>
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
###end article-title 98
###begin article-title 99
###xml 98 106 <span type="species:ncbi:9606">patients</span>
Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer
###end article-title 99
###begin article-title 100
Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression
###end article-title 100
###begin article-title 101
Website title
###end article-title 101
###begin article-title 102
Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk
###end article-title 102
###begin article-title 103
Vegetable/fruit, smoking, glutathione S-transferase polymorphisms and risk for colorectal cancer in Taiwan
###end article-title 103
###begin article-title 104
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients
###end article-title 104
###begin article-title 105
###xml 70 78 <span type="species:ncbi:9606">patients</span>
MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer
###end article-title 105
###begin article-title 106
Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans
###end article-title 106
###begin article-title 107
MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer
###end article-title 107
###begin article-title 108
Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and colorectal cancer: the Fukuoka Colorectal Cancer Study
###end article-title 108
###begin article-title 109
Methylenetetrahydrofolate reductase polymorphism, alcohol intake, and risks of colon and rectal cancers in Korea
###end article-title 109
###begin article-title 110
Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene
###end article-title 110
###begin article-title 111
Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations
###end article-title 111
###begin article-title 112
Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer
###end article-title 112
###begin article-title 113
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
###end article-title 113
###begin article-title 114
Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: a case-control study in Taiwan
###end article-title 114
###begin article-title 115
Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer
###end article-title 115
###begin article-title 116
XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency
###end article-title 116
###begin article-title 117
DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study
###end article-title 117
###begin article-title 118
The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk
###end article-title 118
###begin article-title 119
Deficient DNA repair capacity: a predisposing factor and high risk predictive marker in familial colorectal cancer
###end article-title 119
###begin article-title 120
Oxaliplatin: mechanism of action and antineoplastic activity
###end article-title 120
###begin article-title 121
###xml 149 157 <span type="species:ncbi:9606">patients</span>
Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV
###end article-title 121
###begin article-title 122
Genomic instability and cancer
###end article-title 122
###begin article-title 123
Polymorphisms in DNA repair genes and associations with cancer risk
###end article-title 123
###begin article-title 124
ERCC2/XPD gene polymorphisms and cancer risk
###end article-title 124
###begin article-title 125
ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review
###end article-title 125
###begin article-title 126
XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review
###end article-title 126
###begin article-title 127
DNA repair polymorphisms and risk of colorectal adenomatous or hyperplastic polyps
###end article-title 127
###begin article-title 128
A haplotype encompassing the variant allele of DNA repair gene polymorphism ERCC2/XPD Lys751Gln but not the variant allele of Asp312Asn is associated with risk of lung cancer in a northeastern Chinese population
###end article-title 128
###begin article-title 129
XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis
###end article-title 129
###begin article-title 130
Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes
###end article-title 130
###begin article-title 131
XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects
###end article-title 131
###begin article-title 132
Combination of DNA repair gene single nucleotide polymorphisms and increased levels of DNA adducts in a population-based study
###end article-title 132
###begin article-title 133
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients
###end article-title 133
###begin article-title 134
###xml 196 201 <span type="species:ncbi:9606">human</span>
Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes
###end article-title 134

